Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsHoward Feldman, MD, FRCPC, FAAN (Neurology)
Professor AdjunctAbout
Copy Link
Research
Copy Link
Overview
Medical Research Interests
Dementia; Information Science; Named Groups
ORCID
0000-0002-9258-4538
Research at a Glance
Yale Co-Authors
Frequent collaborators of Howard Feldman's published research.
Publications Timeline
A big-picture view of Howard Feldman's research output by year.
Research Interests
Research topics Howard Feldman is interested in exploring.
James Brewer
Godfrey Pearlson, MA, MBBS
Harlan Krumholz, MD, SM
Vladimir Coric, MD
97Publications
1,216Citations
Publications
2026
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
Cummings J, Atri A, Sano M, Zetterberg H, Scheltens P, Knop F, Johannsen P, Wichmann C, Abschneider R, Leon T, Feldman H. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet 2026 PMID: 41865758, DOI: 10.1016/s0140-6736(26)00459-9.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEarly Alzheimer's diseaseSafety of oral semaglutideCDR-SB scoresFlexible dosingBaseline to weekOral semaglutideCDR-SBAlzheimer's diseaseClinical Dementia Rating-SumPlacebo-controlled phase 3 trialDose of study drugTreatment-emergent adverse eventsMild cognitive impairmentRandomised participantsPlacebo-controlled trialPhase 3 trialConsistent with studiesCognitive impairmentSmall vessel pathologyReduced riskReal-world studyNegative clinical outcomesSymptomatic Alzheimer's diseaseType 2 diabetesDouble-blindValidation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial
Duehring J, Jacobs D, Salmon D, MacKelfresh A, Revta C, Meyer A, Schaeffer M, Schell-Mader S, Wassmann T, Wenzkowski C, Feldman H, Edland S, Group A. Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial. The Journal Of Prevention Of Alzheimer's Disease 2026, 13: 100531. PMID: 41830756, PMCID: PMC12996941, DOI: 10.1016/j.tjpad.2026.100531.Peer-Reviewed Original ResearchAltmetricConceptsCDR-SBOutcome measuresClinical Dementia Rating SumComposite measureStandard power calculationsClinical outcome measuresRandomized Controlled TrialsMild cognitive impairmentEarly Alzheimer's diseaseLinear mixed-effects modelsAlzheimer's diseaseSecondary analysisMixed-effects modelsSample size requirementsCognitive impairmentNeuropsychological test dataFunctional outcomesEfficiency of clinical trialsTrial efficiencyRate sumAD populationSample sizePower calculationsTrialsRandomized clinical trial dataA path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
Reiman E, Alexander R, Langbaum J, Aisen P, Ashton N, Atri A, Barbarino P, Byrd G, Feldman H, Fowler N, Ghisays V, Grill J, Hassenstab J, Heaton G, Herring W, Jack C, Johnson S, Karlawish J, Keach N, Kivipelto M, Krumholz H, Largent E, MaGee-Rodgers T, McDade E, Mielke M, Molina-Henry D, Petersen R, Rabinovici G, Ritchie C, Schindler S, Sperling R, Suárez-Calvet M, Vradenburg G, Weiner M, Welsh-Bohmer K, Zetterberg H, Zuendel M, Mattke S, Cummings J. A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA. The Lancet Neurology 2026, 25: 268-278. PMID: 41722593, DOI: 10.1016/s1474-4422(25)00483-1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSlow cognitive declineBiomarkers of Alzheimer's diseasePrimary prevention therapyAlzheimer's diseaseClinical manifestation of Alzheimer's diseaseManifestation of Alzheimer's diseaseCognitive AssessmentInsurance coverageCognitive declineCognitive impairmentBlood testsPreventive therapyAmyloid plaquesClinical manifestationsDisease-modifying treatmentsDrug treatmentNegative testPeopleAlzheimer's disease therapyApprovalDiseaseAlzheimerAntibody therapyParticipantsDisease-modifyingRelationships between fine memory discrimination and tau burden in two independent cohorts of older adults
Fenton L, Aslanyan V, Jacobs D, Salmon D, Brewer J, Rissman R, Shadyab A, Harrison T, Evans A, LaCroix A, Feldman H, Baker L, Pa J. Relationships between fine memory discrimination and tau burden in two independent cohorts of older adults. Neuropsychologia 2026, 224: 109393. PMID: 41672403, DOI: 10.1016/j.neuropsychologia.2026.109393.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsMnemonic Similarity TaskMemory discriminationHippocampal volumeLogical memoryLower hippocampal volumeHigher tauOlder adultsMnemonic similarity task performanceAssociated with higher tauMedial temporal lobeTraditional memory testsHippocampal integrityMemory testBrain measuresDiscrimination taskAD prevention trialsTemporal lobeAmnestic MCICognitive AssessmentSimilarity taskHippocampalCohort of older adultsAmyloid burdenAmyloid PETMemoryGenetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 Conference.
Field T, Morton S, Brossard-Racine M, Cohen S, Feldman H, Chung A, Newburger J, Puder R, Gurvitz M, Cassidy A. Genetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 Conference. Journal Of The American Heart Association 2026, 15: e042617. PMID: 41553060, PMCID: PMC12919480, DOI: 10.1161/jaha.125.042617.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsBrain healthCongenital heart diseaseRoutine assessmentGene-environment interactionsHeart diseasePsychological outcomesClinical carePsychiatric riskSurgical carePsychiatric sequalaeMultidisciplinary collaborative effortMultidisciplinary expertsNeuroimaging protocolsHealthKnowledge gapsConsensus statementRisk factorsAssessment of brain healthAdultsCareBrainCollaborative effortsRiskResearch cycleRisk modelBaseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease
Scheltens P, Atri A, Feldman H, Zetterberg H, Sano M, Johannsen P, Colombo T, Bardtrum L, Jeppesen R, Hansen C, Cummings J. Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2026, 12: e70200. PMID: 41522368, PMCID: PMC12789876, DOI: 10.1002/trc2.70200.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSafety of semaglutidePhase 3 trialBaseline characteristicsLonger-term efficacyRandomized Controlled TrialsGlucagon-like peptide-1 receptor agonist semaglutidePlacebo-controlled phase 3 trialInclusion criteriaClinical Dementia RatingPrimary readoutBaseline characteristics of participantsProtocol inclusion criteriaDouble-blindOral semaglutideSmall vessel pathologyVessel pathologyAlzheimer's diseaseInhibitor useSymptomatic Alzheimer's diseaseAge of participantsParallel-groupDisease-modifying treatmentsTreatment characteristicsSemaglutideTrial population
2025
The VIVA‐MIND study: Topline Results from Phase 2 RCT of Varoglutamstat in Early AD
Feldman H, Messer K, Zhang J, Quach N, Leger G, Jacobs D, Edland S, Duehring J, MacKelfresh A, Pol A, Revta C, Lupo J, Balasubramanian A, Lama N, Wassmann T, Schaeffer M, Meyer A, Schell‐Mader S, Wenzkowski C, Weber F, Group A. The VIVA‐MIND study: Topline Results from Phase 2 RCT of Varoglutamstat in Early AD. Alzheimer's & Dementia 2025, 21: e105693. PMCID: PMC12741703, DOI: 10.1002/alz70859_105693.Peer-Reviewed Original ResearchCitationsConceptsOral small-molecule inhibitorWell-tolerated dosesFutility analysisDose cohortsPhase 2 RCTDiscontinuations due to AEsBaseline to weekLonger-term safetySignificant treatment benefitDescending dosesPrimary endpointBaseline characteristicsDose selectionABC scorePlaceboSpectral EEGEfficacy assessmentTreatment benefitDoseWeeksTEAEsCDR-sum-of-boxesBiomarker resultsNPYBiomarkersCan Thumbs UP: The Prevention arm of the Canadian Consortium on Neurodegeneration in Aging (CCNA)
Belleville S, Anderson N, Brewster P, Lim A, Montero‐Odasso M, Nygaard H, Feldman H, Chertkow H, Group C. Can Thumbs UP: The Prevention arm of the Canadian Consortium on Neurodegeneration in Aging (CCNA). Alzheimer's & Dementia 2025, 21: e100229. PMCID: PMC12740428, DOI: 10.1002/alz70858_100229.Peer-Reviewed Original ResearchConceptsModifiable risk factorsDementia literacyMultidomain interventionAlzheimer's Disease Knowledge ScaleWeb-based educational interventionSelf-EfficacySecondary outcomesPrimary outcomeHome-based interventionRisk factor mitigationLancet Commission reportRisk factorsRandomized Controlled TrialsDementia preventionDementia riskAlzheimer's SocietyDementia researchDementia casesLifestyle interventionEducational interventionParticipatory researchStandardized cognitive testsKnowledge ScaleLifestyle changesStudy designThe Risks of Clinical Expression of Alzheimer’s Disease (AD) in People with Biomarkers of Alzheimer's Pathology
Feldman H, Villain N, Frisoni G, Dubois B. The Risks of Clinical Expression of Alzheimer’s Disease (AD) in People with Biomarkers of Alzheimer's Pathology. Alzheimer's & Dementia 2025, 21: e107831. PMCID: PMC12740779, DOI: 10.1002/alz70859_107831.Peer-Reviewed Original ResearchConceptsInternational Working GroupPatient journeyLifetime riskMultidomain lifestyle interventionRisk of progression to AD dementiaExpression of Alzheimer's diseaseClinical expression of Alzheimer's diseaseUnimpaired individualsManagement of modifiable risk factorsModifiable risk factorsPresymptomatic groupProgression to AD dementiaCognitively unimpaired individualsLifestyle interventionEvidence reviewAlzheimer pathologyAlzheimer's diseaseCommunication of riskCognitively unimpaired peoplePositive amyloid biomarkerAD dementiaUnimpaired peopleSearch termsAt-riskResilience factorsComparing Traditional and Digital Cognitive Assessments in an Online Dementia Risk Reduction Program: Results from the CAN‐THUMBS‐UP Brain Health Support Program
Brewster P, Jacobs D, Anderson N, Best J, Montero‐Odasso M, Belleville S, Nygaard H, Feldman H, Chertkow H, Group C. Comparing Traditional and Digital Cognitive Assessments in an Online Dementia Risk Reduction Program: Results from the CAN‐THUMBS‐UP Brain Health Support Program. Alzheimer's & Dementia 2025, 21: e106063. PMCID: PMC12741522, DOI: 10.1002/alz70857_106063.Peer-Reviewed Original ResearchConceptsBrain Health AssessmentHealth support programCognitive statusDigital cognitive assessmentBaseline associationsRisk reduction studiesStructural equation modelingSupport programsCognitive AssessmentEcological momentary assessmentAssociated with cognitionRisk reduction programsNeuropsychological batteryAssociated with improvementsMomentary assessmentParticipant characteristicsTime-varying covariatesCognitive endpointsScreening batteryBaseline cognitionCognitive outcomesHealth assessmentStudy baselineDigital assessmentMMRM analysis
Academic Achievements & Community Involvement
Copy Link
Get In Touch
Copy Link